ArticleSurgery today2017
The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
Article in Surgery today, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis.Molecules (Basel, Switzerland) · 2021Pooled it
- Efficacy, Safety, and Cost of Therapy of the Traditional Chinese Medicine, Catalpol, in Patients Following Surgical Resection for Locally Advanced Colon Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Trial
- Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.Medical science monitor : international medical journal of experimental and clinical research · 2018Trial
- Three timepoint perioperative CEA levels are a prognostic factor for recurrence after adjuvant chemotherapy in patients with Stage II and III colorectal cancer.Annals of gastroenterological surgery · 2025Article
- Review
- Predictive value of monocyte to high-density lipoprotein cholesterol ratio and tumor markers in colorectal cancer and their relationship with clinicopathological characteristics.World journal of surgical oncology · 2023Article
- Comparison between a new assay system, ElecsysMolecular and clinical oncology · 2022Article
- The Number of Positive Tumor Markers (NPTM) Achieves Higher Value in the Prognosis Prediction of Gastric Cancer.Disease markers · 2022Article
- Identification of novel neuroblastoma biomarkers in urine samples.Scientific reports · 2021Article
- Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy.Translational cancer research · 2021Article
- Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.Surgery today · 2020Article
- Mutant p53 as an Antigen in Cancer Immunotherapy.International journal of molecular sciences · 2020Review
- Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.International journal of clinical oncology · 2020Article
- Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.International journal of clinical oncology · 2020Article
- Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer.International journal of medical sciences · 2020Observational
- Multi-panel assay of serum autoantibodies in colorectal cancer.International journal of clinical oncology · 2018Article
- Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.Surgery today · 2017Article
- Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery.Clinical journal of gastroenterology · 2017Article
- Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposesSerum P53 antibody (S-P53Ab) is reportedly an effective screening tool for cancer. The aim of this study is to investigate the clinical significance of tumor markers combination in colorectal cancer (CRC) patients.
methodsCarcinoembryonic antigen (CEA), carbohydrate 19 - 9 (CA19-9), and S-P53Ab levels were measured before tumor resection. Of the CRC patients with primary tumor resection at Kumamoto University Hospital, a total of 244 with available preoperative data for these three tumor markers were eligible for this study. The associations of the tumor markers with clinicopathological factors and the prognosis were examined using univariate and multivariate analyses.
resultsS-P53Ab positivity was strongly correlated with rectal cancer, depth of tumor invasion, lymph node metastasis, and lymphatic invasion. The ratio of S-P53Ab positivity was higher than that of CEA or CA19-9 in patients with stage 0/I disease. S-P53Ab had no power to predict the prognosis (P = 0.786). The patients with combined CEA and CA19-9 positivity had a significantly poorer overall survival than those with positivity for neither or only one, and combined CEA and CA19-9 positivity was an exclusive independent prognostic factor (P = 0.034).
conclusionsThe clinical significance of S-P53Ab measurement in CRC patients is limited. However, the combination of CEA and CA19-9 levels may be effective for predicting the outcomes of CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.